Wuhan Weke Medical Completes Hundred-Million-Yuan Series C Funding Round

Investment Circle (ID: pedaily2012) December 21st, by reporter XXX. Wuhan Vickor Medical Technology Co., Ltd. ("Vickor") officially announced that the company has successfully completed its Series C financing round, raising several hundred million RMB. The round was fully led by Bohua Capital, a well-known investment institution based in Liangxi District, Wuxi City.

This round of financing will provide strong financial support for Vickor in areas such as product development, market expansion, and international strategic layout.

Since its establishment in July 2018, Vickor has consistently focused on addressing significant clinical needs in the cardiovascular field, particularly in the minimally invasive interventional treatment of heart failure and structural heart disease. With core competencies in research and development, technical services, production, and sales, the company is committed to building an innovative medical device platform that provides full-cycle cardiovascular solutions, offering advanced products and treatment options to patients and doctors worldwide.

Atrial Shunt Device Receives NMPA's "Special Review Procedure for Innovative Medical Devices" Certification and FDA's "Breakthrough Device" Designation.And independently developed a transcatheter aortic valve replacement system with world-class advanced technology, meeting the dual indications of both stenosis and regurgitation. The procedure does not require general anesthesia or pacemaker assistance, utilizes a minimally invasive interventional approach, and can be completed in just 40 minutes.

Bohua Capital stated, "Vickor's innovation capabilities and market performance in the cardiovascular medical device field are impressive. We believe that through close cooperation and joint efforts, we will surely achieve more brilliant accomplishments in this field."

This article is sourced from Pedaily, original text: https://news.pedaily.cn/202412/544605.shtml